JP2019531261A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531261A5 JP2019531261A5 JP2019503956A JP2019503956A JP2019531261A5 JP 2019531261 A5 JP2019531261 A5 JP 2019531261A5 JP 2019503956 A JP2019503956 A JP 2019503956A JP 2019503956 A JP2019503956 A JP 2019503956A JP 2019531261 A5 JP2019531261 A5 JP 2019531261A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- subject
- level
- biological sample
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 238000000034 method Methods 0.000 claims 12
- 239000012472 biological sample Substances 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 230000003907 kidney function Effects 0.000 claims 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 4
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 4
- 239000000090 biomarker Substances 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- WGNAKZGUSRVWRH-UHFFFAOYSA-N p-cresol sulfate Chemical compound CC1=CC=C(OS(O)(=O)=O)C=C1 WGNAKZGUSRVWRH-UHFFFAOYSA-N 0.000 claims 4
- IHCPDBBYTYJYIL-QVDQXJPCSA-N (R)-2-methylbutyrylcarnitine Chemical compound CCC(C)C(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C IHCPDBBYTYJYIL-QVDQXJPCSA-N 0.000 claims 2
- GFYLSDSUCHVORB-IOSLPCCCSA-N 1-methyladenosine Chemical compound C1=NC=2C(=N)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O GFYLSDSUCHVORB-IOSLPCCCSA-N 0.000 claims 2
- UZTFMUBKZQVKLK-UHFFFAOYSA-N 4-acetamidobutanoic acid Chemical compound CC(=O)NCCCC(O)=O UZTFMUBKZQVKLK-UHFFFAOYSA-N 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 2
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims 2
- JPIJQSOTBSSVTP-PWNYCUMCSA-N D-erythronic acid Chemical compound OC[C@@H](O)[C@@H](O)C(O)=O JPIJQSOTBSSVTP-PWNYCUMCSA-N 0.000 claims 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 2
- QXKAIJAYHKCRRA-FLRLBIABSA-N D-xylonic acid Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)C(O)=O QXKAIJAYHKCRRA-FLRLBIABSA-N 0.000 claims 2
- 238000002965 ELISA Methods 0.000 claims 2
- 239000004386 Erythritol Substances 0.000 claims 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims 2
- RSPURTUNRHNVGF-IOSLPCCCSA-N N(2),N(2)-dimethylguanosine Chemical compound C1=NC=2C(=O)NC(N(C)C)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O RSPURTUNRHNVGF-IOSLPCCCSA-N 0.000 claims 2
- DTERQYGMUDWYAZ-ZETCQYMHSA-N N(6)-acetyl-L-lysine Chemical compound CC(=O)NCCCC[C@H]([NH3+])C([O-])=O DTERQYGMUDWYAZ-ZETCQYMHSA-N 0.000 claims 2
- KTHDTJVBEPMMGL-VKHMYHEASA-N N-acetyl-L-alanine Chemical compound OC(=O)[C@H](C)NC(C)=O KTHDTJVBEPMMGL-VKHMYHEASA-N 0.000 claims 2
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 claims 2
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims 2
- PEDXUVCGOLSNLQ-WUJLRWPWSA-N N-acetyl-L-threonine Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(C)=O PEDXUVCGOLSNLQ-WUJLRWPWSA-N 0.000 claims 2
- PYUSHNKNPOHWEZ-YFKPBYRVSA-N N-formyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC=O PYUSHNKNPOHWEZ-YFKPBYRVSA-N 0.000 claims 2
- HFCPFJNSBPQJDP-UHFFFAOYSA-N O-3-methylglutarylcarnitine Chemical compound [O-]C(=O)CC(C)CC(=O)OC(CC(O)=O)C[N+](C)(C)C HFCPFJNSBPQJDP-UHFFFAOYSA-N 0.000 claims 2
- 229930185560 Pseudouridine Natural products 0.000 claims 2
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 claims 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims 2
- 229960005305 adenosine Drugs 0.000 claims 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 2
- 239000000538 analytical sample Substances 0.000 claims 2
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 claims 2
- 239000004202 carbamide Substances 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims 2
- 229940009714 erythritol Drugs 0.000 claims 2
- 235000019414 erythritol Nutrition 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 2
- 230000024924 glomerular filtration Effects 0.000 claims 2
- 238000003364 immunohistochemistry Methods 0.000 claims 2
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Chemical compound C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 claims 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 2
- 229960000367 inositol Drugs 0.000 claims 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 229940099459 n-acetylmethionine Drugs 0.000 claims 2
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 claims 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 2
- HAEVNYBCYZZDFL-MRVPVSSYSA-N succinyl-L-carnitine Chemical compound C[N+](C)(C)C[C@@H](CC([O-])=O)OC(=O)CCC(O)=O HAEVNYBCYZZDFL-MRVPVSSYSA-N 0.000 claims 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- 229930182821 L-proline Natural products 0.000 claims 1
- JFLIEFSWGNOPJJ-JTQLQIEISA-N N(2)-phenylacetyl-L-glutamine Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CC1=CC=CC=C1 JFLIEFSWGNOPJJ-JTQLQIEISA-N 0.000 claims 1
- KSMRODHGGIIXDV-YFKPBYRVSA-N N-acetyl-L-glutamine Chemical compound CC(=O)N[C@H](C(O)=O)CCC(N)=O KSMRODHGGIIXDV-YFKPBYRVSA-N 0.000 claims 1
- AQTYXAPIHMXAAV-UHFFFAOYSA-N O-methoxycatechol-O-sulphate Chemical compound COC1=CC=CC=C1OS(O)(=O)=O AQTYXAPIHMXAAV-UHFFFAOYSA-N 0.000 claims 1
- QTLRYGUUHGRRNO-UHFFFAOYSA-N S(=O)(=O)(O)O.CC1=C(C(O)=CC=C1)O Chemical compound S(=O)(=O)(O)O.CC1=C(C(O)=CC=C1)O QTLRYGUUHGRRNO-UHFFFAOYSA-N 0.000 claims 1
- ZJUKTBDSGOFHSH-WFMPWKQPSA-N S-Adenosylhomocysteine Chemical compound O[C@@H]1[C@H](O)[C@@H](CSCC[C@H](N)C(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZJUKTBDSGOFHSH-WFMPWKQPSA-N 0.000 claims 1
- 229960005488 aceglutamide Drugs 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 108010087924 alanylproline Proteins 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- OIRDTQYFTABQOQ-UHFFFAOYSA-N ara-adenosine Natural products Nc1ncnc2n(cnc12)C1OC(CO)C(O)C1O OIRDTQYFTABQOQ-UHFFFAOYSA-N 0.000 claims 1
- 238000009739 binding Methods 0.000 claims 1
- XUYANFPPYJSBPU-QMMMGPOBSA-N bisorcic Chemical compound CC(=O)NCCC[C@@H](C(O)=O)NC(C)=O XUYANFPPYJSBPU-QMMMGPOBSA-N 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 238000003119 immunoblot Methods 0.000 claims 1
- 230000000984 immunochemical effect Effects 0.000 claims 1
- 238000013178 mathematical model Methods 0.000 claims 1
- 230000011987 methylation Effects 0.000 claims 1
- 238000007069 methylation reaction Methods 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229960002429 proline Drugs 0.000 claims 1
- -1 quinurenin Chemical compound 0.000 claims 1
- 239000013074 reference sample Substances 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 0 CC(*(C)(C)C)C(*(CCC1)C1C(O)=O)=O Chemical compound CC(*(C)(C)C)C(*(CCC1)C1C(O)=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662367839P | 2016-07-28 | 2016-07-28 | |
| US62/367,839 | 2016-07-28 | ||
| PCT/US2017/044151 WO2018022866A1 (en) | 2016-07-28 | 2017-07-27 | Diagnostic methods, therapeutic agents and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019531261A JP2019531261A (ja) | 2019-10-31 |
| JP2019531261A5 true JP2019531261A5 (enExample) | 2020-09-03 |
| JP6987123B2 JP6987123B2 (ja) | 2021-12-22 |
Family
ID=59579921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503956A Active JP6987123B2 (ja) | 2016-07-28 | 2017-07-27 | 化合物、試薬およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10865183B2 (enExample) |
| EP (1) | EP3491004B1 (enExample) |
| JP (1) | JP6987123B2 (enExample) |
| CN (1) | CN109563127B (enExample) |
| AU (1) | AU2017301949B2 (enExample) |
| CA (1) | CA3032116A1 (enExample) |
| ES (1) | ES2891088T3 (enExample) |
| WO (1) | WO2018022866A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391220B (es) * | 2013-05-14 | 2025-03-21 | Metabolon Inc | Biomarcadores relacionados a la funcion renal y metodos para usar los mismos. |
| US11182920B2 (en) * | 2018-04-26 | 2021-11-23 | Jerry NAM | Automated determination of muscle mass from images |
| TWI669506B (zh) * | 2018-07-06 | 2019-08-21 | 國軍桃園總醫院 | 計算腎絲球過濾率之方法 |
| CN114829940A (zh) * | 2019-12-16 | 2022-07-29 | 希尔氏宠物营养品公司 | 用于诊断和治疗肾病的方法、试剂盒和组合物 |
| WO2021232211A1 (zh) * | 2020-05-19 | 2021-11-25 | 深圳市中医院 | 诊断肾病的标志物以及诊断方法 |
| CN119355249A (zh) * | 2024-09-20 | 2025-01-24 | 长沙都正生物科技股份有限公司 | 苯乙酰谷氨酰胺及其与氧化三甲胺联用作为糖尿病肾病诊断标志物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX391220B (es) | 2013-05-14 | 2025-03-21 | Metabolon Inc | Biomarcadores relacionados a la funcion renal y metodos para usar los mismos. |
| JP5740523B1 (ja) * | 2013-12-11 | 2015-06-24 | 株式会社 資生堂 | 腎不全の早期診断マーカー |
-
2017
- 2017-07-27 ES ES17751177T patent/ES2891088T3/es active Active
- 2017-07-27 JP JP2019503956A patent/JP6987123B2/ja active Active
- 2017-07-27 US US16/321,135 patent/US10865183B2/en active Active
- 2017-07-27 CA CA3032116A patent/CA3032116A1/en active Pending
- 2017-07-27 CN CN201780046847.5A patent/CN109563127B/zh active Active
- 2017-07-27 EP EP17751177.1A patent/EP3491004B1/en active Active
- 2017-07-27 WO PCT/US2017/044151 patent/WO2018022866A1/en not_active Ceased
- 2017-07-27 AU AU2017301949A patent/AU2017301949B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019531261A5 (enExample) | ||
| JP2016520192A5 (enExample) | ||
| Hokamp et al. | Renal biomarkers in domestic species | |
| JP2020112568A (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 | |
| CA2911204C (en) | Biomarkers related to kidney function and methods using the same | |
| JP2019535015A5 (enExample) | ||
| JP2018502286A5 (enExample) | ||
| JP6321080B2 (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 | |
| Winther et al. | Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 study | |
| JP6185035B2 (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 | |
| JP7109441B2 (ja) | 神経変性疾患を判定するための診断補助方法 | |
| JP6186400B2 (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 | |
| EA201290056A1 (ru) | Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности | |
| EP3915584A3 (en) | Immunoassay of s-adenosylmethionine using analogs thereof and personalized therapeutics | |
| ES2690486T3 (es) | Biomarcador de enfermedad renal crónica | |
| WO2014140974A3 (en) | System and method for determining risk of diabetes based on biochemical marker analysis | |
| CY1119797T1 (el) | Λακτοφερινη για χρηση στη διαγνωση και προγνωση της νοσου alzheimer | |
| MX2020009705A (es) | Metodos para la deteccion del riesgo de enfermedad renal cronica en un sujeto y metodo implementado por computadora. | |
| CN107589260A (zh) | 尿液中mmp-7作为肾脏纤维化和慢性肾脏病的生物标志物的用途 | |
| RU2020127365A (ru) | Способы, применения и комплекты для диагностики пародонтита | |
| FI3543702T3 (fi) | Menetelmiä koehenkilön kroonisen munuaissairauden riskin seulomiseksi ja tietokoneella toteutettu menetelmä | |
| NZ703055A (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
| JP2015528562A5 (enExample) | ||
| CN103189394B (zh) | 利用透明质酸评价肾损伤的方法和组合物 | |
| HRP20190341T1 (hr) | Dijagnosticiranje srčane insuficijencije |